Nkarta, Inc. (NKTX)

7.53 +0.04 (+0.53%) At close: 04:00PM EDT

Nkarta, Inc.

1150 Veterans Boulevard
South San Francisco, CA 94080
United States
(925) 407-1049
https://www.nkartatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 150

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul J. Hastings	CEO, President & Director	935.18k	N/A	1960
Ms. Alyssa Levin C.A., CPA	Chief Financial & Business Officer and Principal Accounting Officer	762.4k	N/A	1985
Dr. David R. Shook M.D.	Chief Medical Officer	631.55k	N/A	1978
Dr. Ralph Brandenberger Ph.D.	Chief Technical Officer	N/A	N/A	1969
Dr. James Trager Ph.D.	Chief Scientific Officer	N/A	N/A	1963
Mr. Greg Mann	Vice President of Public Affairs and Investor Relations	N/A	N/A	N/A
Dr. Alicia J. Hager	Chief Legal Officer & Corporate Secretary	590.94k	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Corporate governance

Nkarta, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.